190 related articles for article (PubMed ID: 38538691)
21. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
[TBL] [Abstract][Full Text] [Related]
22. MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.
Li G; Ma L; Feng C; Yin H; Bao J; Wu D; Zhang Z; Li X; Li Z; Yang C; Wang H; Fang F; Hu X; Li M; Xu L; Xu Y; Liang H; Yang T; Wang J; Pan J
BMC Cancer; 2024 Feb; 24(1):220. PubMed ID: 38365636
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B
Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580
[No Abstract] [Full Text] [Related]
24. Multi-Omics Data Integration and Mapping of Altered Kinases to Pathways Reveal Gonadotropin Hormone Signaling in Glioblastoma.
Jayaram S; Gupta MK; Raju R; Gautam P; Sirdeshmukh R
OMICS; 2016 Dec; 20(12):736-746. PubMed ID: 27930095
[TBL] [Abstract][Full Text] [Related]
25. Mining database for the therapeutic targets and prognostic biomarkers among STAT family in glioblastoma.
Li C; Zhou Y; Deng H; Ye Y; Zhao S; Liang S; Cai S; Lin J; Tang Y; Wu Y
Cancer Biomark; 2021; 30(2):179-191. PubMed ID: 33104022
[TBL] [Abstract][Full Text] [Related]
26. Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis.
Nijaguna MB; Patil V; Urbach S; Shwetha SD; Sravani K; Hegde AS; Chandramouli BA; Arivazhagan A; Marin P; Santosh V; Somasundaram K
J Biol Chem; 2015 Sep; 290(38):23401-15. PubMed ID: 26245897
[TBL] [Abstract][Full Text] [Related]
27. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
28. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
[TBL] [Abstract][Full Text] [Related]
29. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine.
Zhao Z; Liu Y; He H; Chen X; Chen J; Lu YC
Brain Res Bull; 2011 Oct; 86(3-4):189-94. PubMed ID: 21807073
[TBL] [Abstract][Full Text] [Related]
30. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
31. Identification of
Lin H; Yang Y; Hou C; Zheng J; Lv G; Mao R; Xu P; Chen S; Zhou Y; Wang P; Zhou D
Genet Test Mol Biomarkers; 2021 May; 25(5):334-345. PubMed ID: 33970702
[No Abstract] [Full Text] [Related]
32. Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.
Jeon H; Byun J; Kang H; Kim K; Lee E; Kim JH; Hong CK; Song SW; Kim YH; Chong S; Kim JH; Nam SJ; Park JE; Lee S
J Transl Med; 2023 Feb; 21(1):69. PubMed ID: 36732815
[TBL] [Abstract][Full Text] [Related]
33. Quantitative proteomics analysis of glioblastoma cell lines after lncRNA HULC silencing.
Ye S; Wu J; Wang Y; Hu Y; Yin T; He J
Sci Rep; 2021 Jun; 11(1):12587. PubMed ID: 34131250
[TBL] [Abstract][Full Text] [Related]
34. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
[TBL] [Abstract][Full Text] [Related]
35. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.
Mukthavaram R; Ouyang X; Saklecha R; Jiang P; Nomura N; Pingle SC; Guo F; Makale M; Kesari S
J Transl Med; 2015 Aug; 13():269. PubMed ID: 26283544
[TBL] [Abstract][Full Text] [Related]
36. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
[TBL] [Abstract][Full Text] [Related]
37. PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
Nawaz Z; Patil V; Paul Y; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Mol Cancer; 2016 Nov; 15(1):74. PubMed ID: 27871300
[TBL] [Abstract][Full Text] [Related]
38. Label-free quantitative proteomics unravels the importance of RNA processing in glioma malignancy.
Bi B; Li F; Guo J; Li C; Jing R; Lv X; Chen X; Wang F; Azadzoi KM; Wang L; Liu Y; Yang JH
Neuroscience; 2017 May; 351():84-95. PubMed ID: 28341197
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatics and machine learning methodologies to identify the effects of central nervous system disorders on glioblastoma progression.
Rahman MH; Rana HK; Peng S; Hu X; Chen C; Quinn JMW; Moni MA
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33406529
[TBL] [Abstract][Full Text] [Related]
40. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
